SANUWAVE Health Inc.
SNWV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SNWV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNWV
SANUWAVE Health Inc. (SNWV) is a medical technology company focused on advanced wound care, having recently refinanced its debt and achieved positive cash flow from operations, though it continues to carry significant debt and a substantial accumulated deficit.
Key risk: High debt leverage
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$48.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
SANUWAVE Health Inc. (SNWV) is a medical technology company focused on advanced wound care, having recently refinanced its debt and achieved positive cash flow from operations, though it continues to carry significant debt and a substantial accumulated deficit.
- Cash and cash equivalents of $9.4 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Total revenue of $9.7 million for the three months ended June 30, 2026, a decrease of approximately 3% compared to the same period in 2025 [sec_mda · as of 2026-08-06].
- Net income of -$0.7 million for the three months ended June 30, 2026 [latest reported financials (authoritative, structured) · as of 2026-06-30].
- Shareholders' equity of $1.6 million as of June 30, 2026 [latest reported financials (authoritative, structured) · as of 2026-06-30].
- Debt outstanding of $18.7 million under Term Loan and $0.7 million drawn under Revolver as of June 30, 2026 [sec_mda · as of 2026-08-06].
What works
- The company generated positive cash flow from operations of $0.8 million in the first half of 2026, compared to negative cash flow of $0.5 million in the same period of 2025 [sec_mda · as of 2026-08-06].
- The refinancing of debt in 2025 extended maturities and provided additional liquidity, alleviating substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-03-26].
- Net income for the year ended December 31, 2025 was $11.8 million, a significant improvement from a net loss of $33.1 million in 2024, driven by non-cash fair value changes and improved operational performance [sec_mda · as of 2026-03-26].
What to weigh
- The company has a significant accumulated deficit from prior years and has historically incurred recurring net losses [sec_mda · as of 2026-03-26].
- Total debt of $19.4 million (Term Loan plus Revolver draw) as of June 30, 2026, far exceeds shareholders' equity of $1.6 million, indicating high financial leverage [sec_mda · as of 2026-08-06].
- Revenue decreased by approximately 3% in the second quarter of 2026 compared to the same period in 2025, suggesting potential headwinds in top-line growth [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $9.4 million”
SEC MD&A · August 6, 2026
Debt outstanding as of June 30, 2026
“$18.7 million outstanding under our Term Loan, and $0.7 million drawn under our Revolver”
SEC MD&A · August 6, 2026
Alleviation of going concern doubt
“These actions have alleviated the substantial doubt about our ability to continue as a going concern.”
SEC MD&A · March 26, 2026
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $19.4M far exceeds equity of $1.6M as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Revenue decline — Q2 2026 revenue decreased 3% year-over-year, indicating potential growth challenges [sec_mda · as of 2026-08-06].
- Accumulated deficit — The company has a significant accumulated deficit from prior years of net losses [sec_mda · as of 2026-03-26].
- Covenant compliance risk — The company must remain in compliance with financial covenants under the JPM Credit Agreement [sec_mda · as of 2026-08-06].
What to watch
- Revenue growth trajectory in upcoming quarters, given the 3% decline in Q2 2026 [sec_mda · as of 2026-08-06].
- Ability to maintain positive cash flow from operations and further reduce debt [sec_mda · as of 2026-08-06].
- Any additional capital structure enhancements or refinancing activities [sec_mda · as of 2026-08-06].
- Compliance with debt covenants and any changes in liquidity position [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run SANUWAVE Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SANUWAVE Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 12.13 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 11 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
57
Total value held
$41.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 697,748 | $12.1M |
| blackrock, inc. | 481,540 | $8.3M |
| stifel financial corp | 251,633 | $4.4M |
| geode capital management, llc | 171,798 | $3.0M |
| state street corp | 140,089 | $2.4M |
| eversource wealth advisors, llc | 43,072 | $2.2M |
| northern trust corp | 62,791 | $1.1M |
| vanguard fiduciary trust co | 49,281 | $852K |
| vanguard portfolio management llc | 44,328 | $766K |
| bridgeway capital management, llc | 40,779 | $705K |
Showing top 10 of 57 institutional holders of SANUWAVE Health Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 12.4%
- Days to cover
- 8.1
- Shares short
- 670,627
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNWV short interestGovernance
Frequently asked questions
What is the AI investment thesis for SANUWAVE Health Inc.?
SANUWAVE Health Inc. (SNWV) is a medical technology company focused on advanced wound care, having recently refinanced its debt and achieved positive cash flow from operations, though it continues to carry significant debt and a substantial accumulated deficit.
Who is the CEO of SANUWAVE Health Inc.?
Mr. Morgan C. Frank is the chief executive officer of SANUWAVE Health Inc. (SNWV).
Where is SANUWAVE Health Inc. headquartered?
SANUWAVE Health Inc. (SNWV) is headquartered in Eden Prairie, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.